In the last trading session, 1.21 million Applied Therapeutics Inc. (NASDAQ:APLT) shares changed hands as the company’s beta touched 1.88. With the company’s per share price at $1.98 changed hands at $0.12 or 6.45% during last session, the market valuation stood at $117.63M. APLT’s last price was a discount, traded about -10.1% off its 52-week high of $2.18. The share price had its 52-week low at $0.50, which suggests the last value was 74.75% up since then. When we look at Applied Therapeutics Inc.’s average trading volume, we note the 10-day average is 2.0 million shares, with the 3-month average coming to 495.69K.
Analysts gave the Applied Therapeutics Inc. (APLT) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.30. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended APLT as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Applied Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.26.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Applied Therapeutics Inc. (NASDAQ:APLT) trade information
Instantly APLT was in green as seen at the end of in last trading. With action 16.47%, the performance over the past five days has been green. The jump to weekly highs of 2.0300 on Monday, 09/18/23 added 6.45% to the stock’s daily price. The company’s shares are showing year-to-date upside of 160.53%, with the 5-day performance at 16.47% in the green. However, in the 30-day time frame, Applied Therapeutics Inc. (NASDAQ:APLT) is 41.43% up. Looking at the short shares, we see there were 1.48 million shares sold at short interest cover period of 4.08 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.67, meaning bulls need an upside of 74.19% from its current market value. According to analyst projections, APLT’s forecast low is $4.00 with $14.00 as the target high. To hit the forecast high, the stock’s price needs a -607.07% plunge from its current level, while the stock would need to soar -102.02% for it to hit the projected low.
Applied Therapeutics Inc. (APLT) estimates and forecasts
Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Applied Therapeutics Inc. will rise 35.00%, while the growth in revenue is estimated to hit -62.50% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -54.10%. The 2023 estimates are for Applied Therapeutics Inc. earnings to increase by 47.10%.
APLT Dividends
Applied Therapeutics Inc. is expected to release its next quarterly earnings report between November 07 and November 13.
Applied Therapeutics Inc. (NASDAQ:APLT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.19% of Applied Therapeutics Inc. shares while 74.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.98%. There are 74.52% institutions holding the Applied Therapeutics Inc. stock share, with Franklin Resources, Inc. the top institutional holder. As of Jun 29, 2023, the company held 12.59% of the shares, roughly 7.95 million APLT shares worth $15.73 million.
VR Adviser, LLC holds the second largest percentage of outstanding shares, with 8.96% or 5.66 million shares worth $11.2 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jul 30, 2023 were Fidelity Select Portfolios – Biotechnology and Franklin Strategic Series-Franklin Biotechnology Discove. With 2.64 million shares estimated at $5.23 million under it, the former controlled 4.18% of total outstanding shares. On the other hand, Franklin Strategic Series-Franklin Biotechnology Discove held about 4.09% of the shares, roughly 2.58 million shares worth around $5.12 million.
